Last reviewed · How we verify
NCT05940987
Phone-based Smoking Cessation Intervention for Patients With Chronic Pancreatitis.(START)
NA trial testing Phone-based smoking cessation intervention in Pancreatitis, Chronic in 382 participants. Completed in 25 February 2025.
25 February 2025
Quick facts
| Lead sponsor | Changhai Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 382 |
| Start date | 28 June 2023 |
| Primary completion | 25 February 2025 |
| Estimated completion | 25 February 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Phone-based smoking cessation intervention
Conditions studied
- Pancreatitis, Chronic — all drugs for Pancreatitis, Chronic →
Sponsor
Changhai Hospital
Who can join
18 and older, any sex, with Pancreatitis, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to explore whether regular telephone intervention in patients with chronic pancreatitis can improve their smoking cessation rate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05940987
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatitis, Chronic
Currently open trials in the same condition.
- NCT07171112 — Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis · Phase 2 · recruiting
- NCT07202559 — Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Sho · NA · recruiting
- NCT06729996 — Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus · Phase 2 · recruiting
- NCT06549725 — Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pa · NA · recruiting
- NCT06330441 — Pancreatic Cancer Screening in a Population at High Risk · NA · recruiting
Other Changhai Hospital trials
Trials by the same sponsor.
- NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
- NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05940987 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
- Last refreshed: 1 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05940987.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing